Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Thomas Müller. (2021) Experimental Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of the Evidence. Journal of Experimental Pharmacology 13, pages 397-408.
Read now
Read now
Thomas Müller. (2020) Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology 16:5, pages 403-414.
Read now
Read now
Thomas Müller & Jan-Dominique Möhr. (2018) Long-term management of Parkinson’s disease using levodopa combinations. Expert Opinion on Pharmacotherapy 19:9, pages 1003-1011.
Read now
Read now
Thomas Müller. (2016) Emerging approaches in Parkinson’s disease – adjunctive role of safinamide. Therapeutics and Clinical Risk Management 12, pages 1151-1160.
Read now
Read now
Articles from other publishers (4)
Olakunle J. Onaolapo, Ademola O. Odeniyi & Adejoke Y. Onaolapo. (2021) Parkinson’s Disease: Is there a Role for Dietary and Herbal Supplements?. CNS & Neurological Disorders - Drug Targets 20:4, pages 343-365.
Crossref
Crossref
Yukihiro Yoshida, Hidetsugu Fujigaki, Koichi Kato, Kyoka Yamazaki, Suwako Fujigaki, Kazuo Kunisawa, Yasuko Yamamoto, Akihiro Mouri, Akifumi Oda, Toshitaka Nabeshima & Kuniaki Saito. (2019) Selective and competitive inhibition of kynurenine aminotransferase 2 by glycyrrhizic acid and its analogues. Scientific Reports 9:1.
Crossref
Crossref
Eyad T. Marashly & Saeed A. Bohlega. (2017) Riboflavin Has Neuroprotective Potential: Focus on Parkinson’s Disease and Migraine. Frontiers in Neurology 8.
Crossref
Crossref
Thomas Müller. (2016) Do we need a new levodopa?. Neural Regeneration Research 11:5, pages 731.
Crossref
Crossref